FDA Slams Centurion For Lax Data Integrity And Misplaced Priorities
The US FDA lambasts Indian drug manufacturer Centurion Laboratories for misplaced priorities and data integrity failings. Workers left product residue on equipment while away for dancing festival. Out-of-specification stability testing results were torn, bagged and replaced with passing results.
You may also be interested in...
Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.